Clinical Trial

Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Disease

Terminated Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
Sponsor decision
Summary
This clinical trial is a study to evaluate the pharmacokinetics of the tablet formulation Pociredir in fasted and fed state participants with Sickle Cell Disease (SCD).
Protocol Amendment History 4 changes
critical Trial terminated 2026-06-19
notable Enrollment reduced: 24 -> 13 participants 2026-06-19
notable Primary completion pushed: 2026-03 -> 2026-05-31 2026-03-31
minor Completion pushed: 2026-04 -> 2026-06 2026-03-31
Trial Details
NCT Number NCT07431398
Lead Sponsor Fulcrum Therapeutics
Conditions Sickle Cell Disease
Enrollment 13 participants
Start Date 2025-12-13
Primary Completion 2026-06-01 (estimated)
Study Completion 2026-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-18